RACK1, a Receptor for Activated C Kinase and a Homolog of the β Subunit of G Proteins, Inhibits Activity of Src Tyrosine Kinases and Growth of NIH 3T3 Cells

por Chang, Betty Y., Conroy, Karen B., Machleder, Eric M., Cartwright, Christine A.
Publicado em 1998

Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK

por Sagiv-Barfi, Idit, Kohrt, Holbrook E. K., Czerwinski, Debra K., Ng, Patrick P., Chang, Betty Y., Levy, Ronald
Publicado no Proc Natl Acad Sci U S A (2015)

The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells

por Chang, Betty Y, Huang, Min Mei, Francesco, Michelle, Chen, Jun, Sokolove, Jeremy, Magadala, Padmaja, Robinson, William H, Buggy, Joseph J
Publicado em 2011

Ibrutinib inhibits pre-BCR(+) B-cell acute lymphoblastic leukemia progression by targeting BTK and BLK

por Kim, Ekaterina, Hurtz, Christian, Koehrer, Stefan, Wang, Zhiqiang, Balasubramanian, Sriram, Chang, Betty Y., Müschen, Markus, Davis, R. Eric, Burger, Jan A.
Publicado no Blood (2017)

Modulating proximal cell signaling by targeting Btk ameliorates humoral autoimmunity and end-organ disease in murine lupus

por Hutcheson, Jack, Vanarsa, Kamala, Bashmakov, Anna, Grewal, Simer, Sajitharan, Deena, Chang, Betty Y, Buggy, Joseph J, Zhou, Xin J, Du, Yong, Satterthwaite, Anne B, Mohan, Chandra
Publicado em 2012

The role of PIM1 in the ibrutinib-resistant ABC subtype of diffuse large B-cell lymphoma

por Kuo, Hsu-Ping, Ezell, Scott A, Hsieh, Sidney, Schweighofer, Karl J, Cheung, Leo WK, Wu, Shiquan, Apatira, Mutiah, Sirisawad, Mint, Eckert, Karl, Liang, Yu, Hsu, Jeff, Chen, Chun-Te, Beaupre, Darrin, Chang, Betty Y
Publicado no Am J Cancer Res (2016)

Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies

por Advani, Ranjana H., Buggy, Joseph J., Sharman, Jeff P., Smith, Sonali M., Boyd, Thomas E., Grant, Barbara, Kolibaba, Kathryn S., Furman, Richard R., Rodriguez, Sara, Chang, Betty Y., Sukbuntherng, Juthamas, Izumi, Raquel, Hamdy, Ahmed, Hedrick, Eric, Fowler, Nathan H.
Publicado no J Clin Oncol (2013)

Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients

por Chang, Betty Y., Francesco, Michelle, De Rooij, Martin F. M., Magadala, Padmaja, Steggerda, Susanne M., Huang, Min Mei, Kuil, Annemieke, Herman, Sarah E. M., Chang, Stella, Pals, Steven T., Wilson, Wyndham, Wiestner, Adrian, Spaargaren, Marcel, Buggy, Joseph J., Elias, Laurence
Publicado em 2013

Bruton’s Tyrosine Kinase (BTK)-dependent immune cell crosstalk drives pancreas cancer

por Gunderson, Andrew J., Kaneda, Megan M., Tsujikawa, Takahiro, Nguyen, Abraham V., Affara, Nesrine I., Ruffell, Brian, Gorjestani, Sara, Liudahl, Shannon M., Truitt, Morgan, Olson, Peter, Kim, Grace, Hanahan, Douglas, Tempero, Margaret A., Sheppard, Brett, Irving, Bryan, Chang, Betty Y., Varner, Judith A., Coussens, Lisa M.
Publicado no Cancer Discov (2015)

Bruton’s tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL)

por Woyach, Jennifer A., Bojnik, Engin, Ruppert, Amy S., Stefanovski, Matthew R., Goettl, Virginia M., Smucker, Kelly A., Smith, Lisa L., Dubovsky, Jason A., Towns, William H., MacMurray, Jessica, Harrington, Bonnie K., Davis, Melanie E., Gobessi, Stefania, Laurenti, Luca, Chang, Betty Y., Buggy, Joseph J., Efremov, Dimitar G., Byrd, John C., Johnson, Amy J.
Publicado em 2014

Disruption of in vivo chronic lymphocytic leukemia tumor-microenvironment interactions by ibrutinib – findings from an investigator initiated phase 2 study

por Niemann, Carsten U., Herman, Sarah E. M., Maric, Irina, Gomez-Rodriguez, Julio, Biancotto, Angelique, Chang, Betty Y., Martyr, Sabrina, Stetler-Stevenson, Maryalice, Yuan, Constance, Calvo, Katherine R., Braylan, Raul C., Valdez, Janet, Lee, Yuh Shan, Wong, Deanna H., Jones, Jade, Sun, Clare C. L., Marti, Gerald E., Farooqui, Mohammed Z., Wiestner, Adrian
Publicado no Clin Cancer Res (2015)

Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma

por Tai, Yu-Tzu, Chang, Betty Y., Kong, Sun-Young, Fulciniti, Mariateresa, Yang, Guang, Calle, Yolanda, Hu, Yiguo, Lin, Jianhong, Zhao, Jian-Jun, Cagnetta, Antonia, Cea, Michele, Sellitto, Michael A., Zhong, Mike Y., Wang, Qiuju, Acharya, Chirag, Carrasco, Daniel R., Buggy, Joseph J., Elias, Laurence, Treon, Steven P., Matsui, William, Richardson, Paul, Munshi, Nikhil C., Anderson, Kenneth C.
Publicado em 2012

Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia

por Byrd, John C., Furman, Richard R., Coutre, Steven E., Flinn, Ian W., Burger, Jan A., Blum, Kristie A., Grant, Barbara, Sharman, Jeff P., Coleman, Morton, Wierda, William G., Jones, Jeffrey A., Zhao, Weiqiang, Heerema, Nyla A., Johnson, Amy J., Sukbuntherng, Juthamas, Chang, Betty Y., Clow, Fong, Hedrick, Eric, Buggy, Joseph J., James, Danelle F., O'Brien, Susan
Publicado em 2013

Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial

por O’Brien, Susan, Furman, Richard R, Coutre, Steven E, Sharman, Jeff P, Burger, Jan A, Blum, Kristie A, Grant, Barbara, Richards, Donald A, Coleman, Morton, Wierda, William G, Jones, Jeffrey A, Zhao, Weiqiang, Heerema, Nyla A, Johnson, Amy J, Izumi, Raquel, Hamdy, Ahmed, Chang, Betty Y, Graef, Thorsten, Clow, Fong, Buggy, Joseph J, James, Danelle F, Byrd, John C
Publicado em 2013

Resistance Mechanisms for the Bruton’s Tyrosine Kinase Inhibitor Ibrutinib

por Woyach, Jennifer A., Furman, Richard R., Liu, Ta-Ming, Ozer, Hatice Gulcin, Zapatka, Marc, Ruppert, Amy S., Xue, Ling, Li, Daniel Hsieh-Hsin, Steggerda, Susanne M., Versele, Matthias, Dave, Sandeep S., Zhang, Jenny, Yilmaz, Ayse Selen, Jaglowski, Samantha M., Blum, Kristie A., Lozanski, Arletta, Lozanski, Gerard, James, Danelle F., Barrientos, Jacqueline C., Lichter, Peter, Stilgenbauer, Stephan, Buggy, Joseph J., Chang, Betty Y., Johnson, Amy J., Byrd, John C.
Publicado em 2014

Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma

por Wang, Michael L., Rule, Simon, Martin, Peter, Goy, Andre, Auer, Rebecca, Kahl, Brad S., Jurczak, Wojciech, Advani, Ranjana H., Romaguera, Jorge E., Williams, Michael E., Barrientos, Jacqueline C., Chmielowska, Ewa, Radford, John, Stilgenbauer, Stephan, Dreyling, Martin, Jedrzejczak, Wieslaw Wiktor, Johnson, Peter, Spurgeon, Stephen E., Li, Lei, Zhang, Liang, Newberry, Kate, Ou, Zhishuo, Cheng, Nancy, Fang, Bingliang, McGreivy, Jesse, Clow, Fong, Buggy, Joseph J., Chang, Betty Y., Beaupre, Darrin M., Kunkel, Lori A., Blum, Kristie A.
Publicado no N Engl J Med (2013)

Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes

por Dubovsky, Jason A., Beckwith, Kyle A., Natarajan, Gayathri, Woyach, Jennifer A., Jaglowski, Samantha, Zhong, Yiming, Hessler, Joshua D., Liu, Ta-Ming, Chang, Betty Y., Larkin, Karilyn M., Stefanovski, Matthew R., Chappell, Danielle L., Frissora, Frank W., Smith, Lisa L., Smucker, Kelly A., Flynn, Joseph M., Jones, Jeffrey A., Andritsos, Leslie A., Maddocks, Kami, Lehman, Amy M., Furman, Richard, Sharman, Jeff, Mishra, Anjali, Caligiuri, Michael A., Satoskar, Abhay R., Buggy, Joseph J., Muthusamy, Natarajan, Johnson, Amy J., Byrd, John C.
Publicado em 2013